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Abstract
Background
Chronic hepatitis C virus infection is a major cause of liver disease in Switzerland and car-
ries a significant cost burden. Currently, only conservative strategies are in place to mitigate
the burden of hepatitis C in Switzerland. This study expands on previously described model-
ing efforts to explore the impact of: no treatment, and treatment to reduce HCC and mortali-
ty. Furthermore, the costs associated with untreated HCV were modeled.
Methods
Hepatitis C disease progression and mortality were modeled. Baseline historical assump-
tions were collected from the literature and expert interviews and strategies were developed
to show the impact of different levels of intervention (improved drug cure rates, treatment
and diagnosis) until 2030.
Results
Under the historical standard of care, the number of advanced stage cases was projected to
increase until 2030, at which point the annual economic burden of untreated viremic infec-
tions was projected to reach €96.8 (95% Uncertainty Interval: €36 – €232) million. Scenarios
to reduce HCV liver-related mortality by 90% by 2030 required treatment of 4,190F2 or
3,200F3 patients annually by 2018 using antivirals with a 95% efficacy rate. Delaying the
implementation of these scenarios by 2 or 5 years reduced the impact on mortality to 75%
and 57%, respectively.
Conclusions
With today’s treatment efficacy and uptake rates, hepatitis C disease burden is expected to
increase through 2030. A substantial reduction in disease burden can be achieved by
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means of both higher efficacy drugs and increased treatment uptake. However, these ef-
forts cannot be undertaken without a simultaneous effort to diagnose more infections.
Introduction
TheWorld Health Organization calls hepatitis C virus (HCV) a silent disease [1]. This is not
only due to its symptomless clinical course, even when it has progressed to advanced liver dis-
ease, but also to the frequency with which it is overlooked and under-funded in the political
sphere [2]. HCV infection takes a chronic course in about 80% of those infected, posing a sub-
stantial risk of progressing to cirrhosis and hepatocellular carcinoma (HCC) [3–5]. Although
HCV incidence and prevalence are decreasing, morbidity and mortality will increase in the
next years as complications of end stage liver disease occur mostly 20–30 year after infection
putting a significant burden on the health care and economical system [6].
There is evidence that treatment leading to a sustained viral response (SVR) can reverse the
effects of early stage fibrosis, and slow the progression of cirrhosis into decompensation or HCC
[7,8]. Thus, prompt identification and management of cases is imperative for mitigation of the
increasing burden of disease resulting from an aging population [9]. There is not currently a na-
tional screening strategy to identify HCV cases in Switzerland. However, the Federal Office of
Public Health (FOPH) has collected and maintained a notification database for all positive tests
for non-A, non-B hepatitis and HCV since 1988 [9,10]. The aim of this study is to expand on re-
cent modeling efforts through novel scenario development to assist in the development of na-
tional strategies for HCV control. Additionally, the cost of untreated HCV was analyzed.
Methods
HCV disease progression model
A detailed description of the HCV disease progression model was described previously [11]
and is provided in S1 Fig and S1 Table. The model was populated and calibrated using Swiss
specific assumptions (S1 File, S2 Table) to forecast the future burden of HCV by stage of the
disease. For consistency, the HCV population by sequelae in 2030 was used for comparison to
the 2013 populations in the analyses below, unless noted otherwise.
Model Outcomes. Model outcomes included annual estimates of total viremic infections
as well as viremic infections by disease sequelae (e.g. fibrosis, cirrhosis and HCC). Deaths at-
tributable to background mortality and liver related mortality were also tracked annually. The
forecasts were collected for each scenario described below.
Epidemiology of the HCV infected population. A thorough review of published litera-
ture and government reports was conducted to describe the total population and HCV preva-
lent population, and meetings with key opinion leaders and HCV experts in Switzerland were
held to gain consensus surrounding the inputs. Some of the inputs summarized below have
been described in more detail elsewhere [12].
Base (1.6%) and high (1.8%) estimates for anti-HCV prevalence were chosen from a modeling
study completed in 1998 [13] with a low estimate of 0.8% [9]. The age and gender distribution of
HCV infected individuals was estimated using notification data from the FOPH [14] and the ge-
notype (G) distribution was available through the Swiss Hepatitis C Cohort Study [15]. The model
only tracks viremic cases, and a viremic rate of 79.7% was chosen to adjust antibody estimates
[16]. Applying the anti-HCV prevalence and viremic rate estimates to Swiss population data [17]
indicates there were approximately 88,000 (45,400–102,000) viremic HCV infections in 1998.
Economic Impact of Hepatitis C
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Notification data and analysis from the FOPH suggest that 41,300 anti-HCV (32,900 vire-
mic) infections were diagnosed as of 2013, with approximately 1,310 new anti-HCV (1,050 vi-
remic) diagnoses occurring annually since 2011 [12,14].
The number of annual new cases was defined as the sum of acute infections progressing to
chronicity plus chronic (viremic) infections entering Switzerland through immigration. The
FOPH reports that 711 acute infections of HCV were declared from 2002–2011, or approxi-
mately 71 acute infections annually [18]. Since only 20–25% of acute infections are symptomat-
ic [9] and an estimated 79.7% become chronic, there may have been as many as 283 new
chronic infections occurring annually. Additionally, during 2002–2011, it was estimated that as
many as 8,820 anti-HCV infections entered Switzerland through migration (immigrants minus
emigrants) [19,20], or approximately 700 viremic infections annually, based on the assumption
that only 79.7% of those anti-HCV+ are viremic [16]. Combined, these data suggest that up to
985 new viremic infections occur annually in Switzerland. The analysis assumed the number of
new infections and re-infection will remain constant in the future.
Background mortality was estimated using the Human Mortality Database of the University
of Berkeley and the mortality rates recorded by the Swiss Federal Statistics Office (FSO)
[21,22]. Additionally, increased mortality among active injecting drug users (IDUs) was esti-
mated using a standardized mortality ratio (SMR) of 5.5 for individuals between 15 and 44
years of age given the effective harm reduction programs in place in the Switzerland [23–25].
Although IDU was reported as a risk factor among 65% of all HCV infections, only 21% were
estimated to be active users [26–29].
Healthcare cost data. For both in- and outpatients the costs generated in 2012 were ob-
tained from the financial department at the University Hospital in Zürich. For each patient the
fibrosis stage according to the Metavir staging system was obtained either from liver biopsy or
estimated from Fibroscan reports. In case the fibrosis stage was obtained by either method and
the results were not in agreement, the biopsy data was used. The records included a history of
liver transplantation, HCC diagnosis or if the patient was being treated for the HCV infection.
In addition, all in-patients hospitalized in 2012 with acute HCV (International Classification of
Diseases (ICD) 10 code: B17.1) and/or chronic HCV (ICD 10 code: B18.2), and the respective
Swiss Procedure Code (CHOP) codes were extracted from the hospital database. Liver trans-
plant reimbursement costs were available through the hospital, so data obtained through in-
and outpatient records were used solely to estimate the cost of subsequent years of care follow-
ing a liver transplantation. The cost of antiviral therapy was excluded from this analysis. Al-
though all costs were obtained from a single-center, a consensus was found within the group of
experts that these are representative for Switzerland.
Previous liver transplant was noted in outpatient records, and was defined by an ICD 10
code of T864 (or subsets). HCC was defined as HCC in outpatient records, or an in- patient
ICD 10 code of C220. Decompensated cirrhosis was defined as an in- patient ICD 10 code of
R18, G92 or I85, in the absence of more advanced liver disease. Cirrhosis was defined as F4 in
outpatient records or an in- patient ICD 10 code of K746, in the absence of more advanced
liver disease. Fibrosis data was only available from outpatient records.
Healthcare cost analysis (excluding treatment). Healthcare costs were calculated by
matching in-patient and outpatient records and calculating a total cost for each patient. Pa-
tients were allocated to the most severe disease stage diagnosed and average cost was calculated
across the total number of patients in the stage (Table 1). Finally, the average annual cost for
patients with fibrosis and compensated cirrhosis were adjusted as follows to account for the
zero costs incurred by the undiagnosed population.
Averageannualcost ¼ Annualcost  %Diagnosed
Economic Impact of Hepatitis C
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This approach ignored the healthcare costs associated with HCV related comorbidities if
the patients were not diagnosed with HCV. At the time of this analysis, cost of the new thera-
pies was not available and treatment cost was excluded.
Sensitivity analysis. The uncertainty in assumptions/inputs was captured as a range (S3
Table) using a Beta-PERT distribution. Crystal Ball, an Excel add-in by Oracle was used to run
Monte Carlo simulations to determine the 95% uncertainty intervals and sensitivity analysis.
Scenario development
Under the base case scenario (current standard of care), an estimated 1,100 patients were treat-
ed annually in Switzerland [12,30]. The pool of patients eligible for treatment was determined
by the number of diagnosed patients who were age and fibrosis stage eligible, with no contrain-
dications to treatment and who were willing to accept treatment. It was assumed that all pa-
tients between 15–69 years of age who had a fibrosis score of F2 or higher on the Metavir scale
were eligible for standard and triple therapy. The average SVR for this population was 61% for
G1 and G4, and 70% for G2 and G3. Additionally, it was assumed that 40% of patients were ei-
ther contraindicated or refused current therapies [31,32].
Scenarios were modeled with changes to SVR, medical eligibility, treatment uptake, diagno-
sis rates, treated patient segments and the timing of access to the new therapies.
1. Discontinuation of treatment—all therapies were discontinued in 2014 to assess the effect of
current treatment standards.
2. Increased treatment uptake and efficacy to achieve 50% or 90% reduction in mortality—two
scenarios were developed to achieve a 50% and 90% reduction in liver-related disease bur-
den and mortality by 2030 treatingF2 patients using antivirals with a 95% efficacy rate.
Additionally, scenarios were run where the fibrosis stage threshold for starting therapy was
increased toF3 or F4 (including decompensated cirrhosis and transplant), keeping con-
stant the goal of 50% and 90% reductions in mortality
3. Impact of time and patient segment—the impact of time was assessed by delaying theF2-
90%-reduction scenario by 2 or 5 years. The impact of patient segment was assessed by re-
stricting treatment toF3 or F4 patients. For all of these scenarios, SVR increases, as well as
the number of treated patients remained the same as in theF2-90%-reduction scenario.
Table 1. Estimated cost per patient per year (excluding the cost of antiviral therapy), by disease stage, in 2011 Euros.
Disease Stage Base cost* (€) Low Cost** (€) High Cost*** (€)
Chronic HCV (F0) 104 21 643
F1 169 14 1,100
F2 381 71 1,681
F3 866 134 4,618
Compensated Cirrhosis 2,174 98 16,352
Decompensated Cirrhosis 16,457 4,223 30,117
Hepatocellular Carcinoma 13,567 1,983 58,246
Liver Transplant 100,174 87,796 239,110
Liver Transplant—Subseq. Yrs 15,473 193 171,851
(* Base costs were calculated as described above, ** Low costs represent the minimum cost associated with each stage, *** High costs represent the
maximum cost associated with disease each stage).
doi:10.1371/journal.pone.0125214.t001
Economic Impact of Hepatitis C
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4. 90% reduction ‘hybrid’ scenario—theF2-90%-reduction was modified to initially restrict
treatment to F4 patients beginning in 2014. Restrictions were relaxed in 2016 (to include
F3) and 2018 (to includeF2).
Results
Base Case
Peak viremic prevalence of chronic HCV infection was reached in 2003 at 88,600 (41,500–
98,500) viremic infections, and by 2013 there were 82,700 (37,200–93,400) infections (Fig 1).
Although prevalence was estimated to decline to 63,200 (25,900–71,800) viremic infections in
2030, assuming that all inputs and outputs remain stable over time (including treatment uptake
and efficacy) the number of individuals with advanced liver disease increased. The number of
compensated cirrhosis (n = 12,700), decompensated cirrhosis (n = 1,790) and HCC (n = 745)
cases were forecasted to increase 50%, 57% and 84% as compared to the 2013 populations (Fig
2). Additionally, by 2030, liver related mortality was forecasted to increase 72% (from 380
deaths to 650 deaths) as the HCV population ages (Fig 2).
The 2013 annual healthcare cost of viremic HCV (excluding antiviral treatment costs) was
estimated at €74 (€36 –€157) million. The annual cost was projected to peak in 2030 at €97
(€36 –€232) million (Fig 1). Under the base case, the cumulative healthcare costs for 2013–
2030 were estimated at €1,581 (€620 –€4,053) million.
The results of the sensitivity analysis are shown in S2 Fig. The analysis showed that the un-
certainty in the anti-HCV prevalence is the driver of uncertainty accounting for most of the
observed variability.
Discontinuation of Treatment
In the absence of treatment, viremic prevalence was forecasted to decrease at a slower rate than
under the base case, with 73,400 viremic cases in 2030. Additionally, by 2030, the numbers of
individuals with compensated cirrhosis and decompensated cirrhosis were projected to
Fig 1. Total viremic cases (blue) and associated healthcare costs (red), by year, 1950–2050 (the upper and lower bounds represent 95%
uncertainty intervals).
doi:10.1371/journal.pone.0125214.g001
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increase to 16,485 and 2,280 cases, respectively. The number of individuals with HCC, caused
by HCV infection, was projected to increase to 910 cases, a 22% increase over the base case.
Under this scenario, liver related mortality was projected to increase from 380 deaths in 2013
to 800 deaths in 2030, a 23% increase over the base case (Fig 3a).
Discontinuing treatment was associated with a projected €190 million per year increase in
net costs from 2013–2030 as compared with the base case (cumulative cost = €1,771 million).
The increase in cost was a result of the progression to more advanced disease by those who
would have been cured under the base scenario. In 2030, annual costs were projected to be 24%
higher than under the base case.
Treatment uptake required to achieve 50% or 90% reduction in mortality
In order to attain 50% reduction in mortality while restricting access toF2 patients, an in-
crease in treatment of up to 2,550 patients annually by 2018, with 95% SVR therapies, would be
required (Table 2, Fig 3b). This strategy increases the number of patients, with a 50% increase
in the number of patients treated beginning in 2016 (1,640 total) and a 155% increase begin-
ning in 2018 (2,550 total). The model was designed to provide a warning when an insufficient
number of patients was available for treatment. In order for treatment to increase at this rate,
improved screening and diagnosis (i.e. from 1,050 viremic diagnoses annually in 2013 to 2,370
viremic diagnoses annually in 2020) and the treatment of patients up to 74 years of age
were necessary.
Fig 2. Change in disease burden, by year, 1950–2030 (the upper and lower bounds represent 95% uncertainty intervals).
doi:10.1371/journal.pone.0125214.g002
Economic Impact of Hepatitis C
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Fig 3. Exploratory scenario outputs, 2013–2030. (A) HCV-related liver-related deaths, by scenario; (B) Maximum number of patients treated annually to
achieve 50% or 90% reduction, by METAVIR stage treated; (C) Impact of treatment restrictions (restriction toF3 or F4) on a strategy to reduce liver-related
mortality by 90%, and the annual number of patients treated before ‘running out of patients’; (D) Impact of 2-year and 5-year delays on a strategy to reduce
liver-related mortality by 90%.
doi:10.1371/journal.pone.0125214.g003
Table 2. Maximum annual treatment and diagnosis required for 50% and 90% reductions in HCC/Mortality, by treated stage.
Scenario Annual Treatment Cumulative Treatment Annual Diagnosis
Max 2030 2013–2030 Max
Base 1,100 19,700 1,050
50% Reduction F2 2,550 39,700 2,370
F3 1,850 30,000 2,370
F4 1,095 19,700 3,580
90% Reduction F2 4,190 1,430 58,000 5,370
F3 3,200 1,640 46,900 6,010
F4* 1,750 1,415 26,100 7,900
Hybrid 4,190 1,495 57,955 5,370
* A 90% reduction in mortality could not be attained if treatment was restricted to the F4 population.
doi:10.1371/journal.pone.0125214.t002
Economic Impact of Hepatitis C
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To attain 90% reduction in mortality while limiting access toF2 patients, an increase in
treatment of up to 4,190 patients annually by 2018, with 95% SVR therapies, would be required
(Table 2, Fig 3b). This strategy increases the number of patients gradually, with a 50% increase
in the number of treated patients beginning in 2014 (1,640 total), 50% increase beginning in
2016 (2,460 total), and 70% increase beginning in 2019 (4,190 total). In order for treatment to
increase at this rate, improved screening and diagnosis is necessary (from 1,050 viremic diag-
noses annually in 2013 to 5,370 viremic diagnoses annually in 2020) and the treatment of pa-
tients up to 79 years of age is compulsory.
Restricting therapy access toF3 or F4 patients decreased the treatment rate required to reach
50% or 90% reduction (Table 2, Fig 3b), however the number of viremic patients diagnosed annu-
ally had to be increased, as shown in Table 2, to have sufficient number of patients to treat. Fur-
thermore, 90% reduction could not be attained if treatment was restricted to the F4 population.
Scenario analyses around theF2-90% reduction scenario
Restricting treatment toF3 patients resulted in a rapid initial decrease in liver-related mortali-
ty, however liver related deaths in 2030 were very similar to those under theF2-90%-reduction
scenario (F3–70 deaths in 2030,F2–65 deaths in 2030) (Fig 3c, Table 3). Treating 4,190F3
patients annually was only sustainable until 2020, after which time the model predicted that only
2,500–3,400 patients were available to treat annually. Since fewer patients were treated cumula-
tively, the number of viremic infections increased 35%, as compared with theF2 scenario.
Restrict to F4—Restricting treatment to F4 patients resulted in a very rapid initial decrease
in liver related deaths followed by a plateau (Fig 3c). By 2030, there were 165 liver related
deaths annually, 154% more than under theF2 scenario (65 cases as shown in Table 3). The
viremic prevalence in 2030 was 57,500—a 95% increase from theF2 scenario (29,400).
Table 3. Model outputs by scenario, and scenario analysis surroundingF2, 90% reduction in HCC/Mortality scenario.
Model Outputs
by Scenario
HCC Mortality Prevalence Decomp Cirrhosis Comp Cirrhosis
2013 2030 2013 2030 2013 2030 2013 2030 2013 2030
Base 405 745 380 650 82,700 63,200 1,140 1,790 8,520 12,700
HCC Mortality Prevalence Decomp Cirrhosis Comp Cirrhosis
Scenario Peak (Year) 2030 Peak (Year) 2030 2030 Peak (Year) 2030 Peak (Year) 2030
Modeled
Scenarios
Discontinued
Treatment
910 (2030) 910 800 (2030) 800 73,400 2,280 (2030) 2,280 16,480 (2030) 16,485
F2, 50%
Reduction in
Mortality
485 (2020) 350 455 (2019) 320 42,600 1,280 (2017) 730 9,250 (2017) 4,990
F2, 90%
Reduction in
Mortality
455 (2018) 70 435 (2018) 65 29,400 1,270 (2016) 110 8,820 (2015) 825
Hybrid, 90%
Reduction in
Mortality
420 (2015) 75 420 (2019) 70 29,500 1,230 (2015) 120 8,670 (2014) 895
Scenario
Analysis, Max
4,190 tx / yr
F2, 90%
Reduction
2- year delay 500 (2020) 100 470 (2020) 115 30,000 1,360 (2018) 170 9,450 (2017) 1,235
5-year delay 565 (2023) 230 525 (2019) 260 35,700 1,500 (2021) 450 10,420 (2020) 3,010
Treat F3 440 (2017) 65 430 (2019) 70 40,000 1,260 (2016) 115 8,670 (2014) 1,140
Treat F4 420 (2015) 150 420 (2019) 165 57,500 1,230 (2015) 250 8,670 (2014) 3,880
doi:10.1371/journal.pone.0125214.t003
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Delay by 2 years—Delaying theF2-90%-reduction scenario’s implementation by two
years resulted in a 77% increase in liver related mortality by 2030 (Fig 3d, Table 3).
Delay by 5 years—Delaying the implementation by five years resulted in a 300% increase in
liver related mortality by 2030 (Fig 3d, Table 3).
Hybrid scenario to reduce mortality by 90%
The hybrid approach to reduce mortality by 90% resulted in both a rapid initial decrease in
liver-related deaths and allowed for sustained treatment of 4,190 patients annually until 2028.
Thus, the viremic prevalence in 2030 was similar to that of theF2-90%-reduction scenario,
with 29,500 cases (compared with 29,400) (Table 3). The impact of the hybrid approach on re-
ductions in compensated and decompensated cirrhosis, as well as HCC can be seen in Fig 4.
Discussion
Despite a decrease in the rate of new infections in Switzerland, HCV poses a considerable pub-
lic health threat caused by secondary liver related morbidity and mortality of those already in-
fected. This is further complicated by the fact that less than 50% of the infected population is
aware of their infection [9].
With today’s treatment efficacy and uptake rates, the number of cases of HCV induced cir-
rhosis, decompensated cirrhosis and HCC is expected to steadily increase until 2030. It is im-
portant to note, however, that prevention (of disease or mortality) is an intangible outcome
and recognition of current efforts is worth acknowledging. The analysis in which treatment
was discontinued showed a 23% increase in mortality compared with current treatment, sug-
gesting the importance of, at minimum, maintaining the current standard of care to prevent in-
creased morbidity and mortality.
A key insight of this analysis was identification of factors that drive a reduction in HCVmor-
bidity, mortality and total infections. A reduction in end stage liver diseases (ESLD) and liver re-
lated deaths (LRD) is achievable by focusing treatment on patients with high fibrosis (F3 or
F4); however, a significant reduction in the total number of infections cannot be achieved unless
treatment is expanded to patients in the early stages of fibrosis. The trade-off to achieve a
Fig 4. Projected base and hybrid scenario results for cirrhosis, decompensated cirrhosis and HCC, 1950–2050.
doi:10.1371/journal.pone.0125214.g004
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reduction in total infections is the requirement for a higher number of patients to be treated to
achieve the same level of reduction in ESLD and LRD by 2030. A significant reduction in the
total number of infection is not achievable under the current treatment paradigm.
If managing the drug costs while minimizing liver related deaths, is the primary goal, then
focusing on patients with late stage of fibrosis would achieve a significant reduction in HCV
morbidity and mortality while treating fewer patients. Once this population has been depleted,
treatment can be expanded to patients with a lower fibrosis (F2 beforeF1 beforeF0) as
demonstrated by the hybrid strategy. This strategy ensures that the patients who need treat-
ment most are given a priority while managing the treatment cost and the increased demand
on the healthcare system.
However, the analysis also showed that focusing treatment exclusively on F4 patients was
not as effective in reducing LRD. This is driven by three factors: only those who are diagnosed
can be treated, not all individuals with fibrosis score of F4 are diagnosed and individuals who
are F4 tend to be older. Aside from the fact that decompensated cirrhotics cannot be treated
with any combination therapy containing interferon, individuals who are F4 and not diagnosed
will continue to progress and age. Once they pass age of 74, the analysis considers them ineligi-
ble for treatment. These individuals are ineligible for treatment independent of their future di-
agnosis status. In addition, studies have shown that some cirrhotic patients will continue to
progress to ESLD after achieving SVR [8]. Thus, some portion of the F4 patients who are diag-
nosed, treated, and achieve SVR will continue to progress. Treating patients after they are cir-
rhotic is less effective than preventing them from becoming cirrhotic. Expansion of treatment
toF3 captured these individuals while they were younger than 74 years old and prevented
disease progression.
This highlights another important observation—the impact of treatment to prevent disease
progression. As shown in Fig 3C, theF3 strategy was more effective in reducing LRD after
2021 as compared to the F4 strategy. This was because patients who achieved SVR were pre-
vented from progressing to cirrhosis and subsequently ESLD. Those F3 cases who are undiag-
nosed will still have a chance to be diagnosed when they reach F4 thus improving the odds of
capturing and treating them before they reach ESLD.
A strategy to reduce HCV prevalence by 90% in Switzerland must involve treatment regard-
less of liver disease stage. This approach would require a significant expansion of the current
treatment capacity, possibly through appropriately trained mid-level providers and/or primary
care physicians [33], i.e. according to a task shifting strategy already effectively tested for HIV
infection [34,35] and recently proposed for HCV [36]. Once well tolerated and easy to adminis-
ter therapies become available, a test-and-treat approach (where an HCV diagnosis is followed
by a treatment offer) may be possible. The availability of such simplified regimens, effective for
all patients independently of their baseline and on-treatment features, may further raise the
trend of treating HCV as an infectious disease.
Increased detection and diagnosis of viremic cases is a primary requirement for all strategies
aiming to significantly impact HCV disease burden. Therefore, enhancing detection rates in
Switzerland has high priority in order to control the HCV epidemic. Birth cohort screening
among individuals born between 1945 and 1965 has proven effective in the United States (US)
[37], and a similar approach could be considered for Switzerland. The Swiss HCV epidemic is
younger than that of the US, with 70% of the viremic population born between 1950 and 1975.
Screening programs targeting this population are estimated to have the greatest success in iden-
tifying new cases.
Given the higher SVR of the new therapies, delays in access lead to slower reductions in
mortality, morbidity and total infections between 2013 and 2030 (Table 3). A 2 and 5 years
delay in theF2 strategies lead to 80% and 300% higher liver related deaths in years 2030.
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There were a number of limitations in this study that impact the accuracy of our base pro-
jections. Sensitivity analysis identified prevalence as the largest driver of uncertainty in the
Swiss model—accounting for 88% of the variability. A wide range around prevalence was pur-
posefully chosen to account for the variability in currently cited estimates; however, this under-
scores the need for a reliable, population based survey. Though not captured in the sensitivity
analysis, additional uncertainty surrounds the notification data. Mandatory reporting of HCV
in Switzerland is based on a passive surveillance system and is therefore subject to underreport-
ing. However, this underreporting is limited by the fact that all cases are laboratory confirmed
and that many laboratories have automated routines to report positive cases. Additionally,
many patients have been tested several times, which increases the likelihood of cases being re-
ported. Finally, there is uncertainty surrounding the source of infection, as 40% of reports cited
“unknown” or missing routes of transmission. Percent of transmission due to IDU and transfu-
sion were therefore calculated only among cases with a known exposure.
Finally, the analysis focused on ESLD and mortality and the impact of treatment as preven-
tion was not considered. The latter would result in a faster drop in the total number of HCV in-
fections by reducing HCV transmission. The impact of treatment as prevention on ESLD and
LRD would be minimal in the time frame considered (2013–2030) since new infected individu-
als will take time to progress to ESLD.
In order to improve detection and treatment of HCV, Switzerland needs to coordinate its ef-
forts nationwide. While the strategies mentioned in this paper are contingent upon the avail-
ability of new potent therapies with higher cure rates and improved treatment experience, the
current standard of care shows a reduction in disease burden as compared to the modeled ef-
fects of discontinuing all treatment. Further modeling analyses are needed to evaluate the cost
effectiveness of these aforementioned strategies, including the cost of medication. The analysis
presented here highlights the need to develop timely strategies to reduce the effects of chronic
HCV disease in Switzerland.
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